Patients with hormone receptor-positive DCIS found to have the invasive disease can be treated with adjuvant hormonal therapy, as it confers a survival benefit, while adjuvant hormonal therapy is not indicated for hormone receptor-negative tumors [19]. The gene discussed is NR4A1; the disease is ductal breast carcinoma in situ.